Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Paclitaxel 7Specimen Handling 6Radiotherapy 4Magnetic Resonance Spectroscopy 4Biopsy 4pembrolizumab 3Taxes 3Nivolumab 3Carboplatin 3trastuzumab deruxtecan 2olaparib 2ceralasertib 2aflibercept 2X-Rays 2Psychiatric Rehabilitation 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Ifosfamide 2Gene Expression Profiling 2Fulvestrant 2Filgrastim 2Fentanyl 2Doxorubicin 2Bevacizumab 2trifluridine tipiracil drug combination 1toripalimab 1tinostamustine 1spartalizumab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × rebastinib × Sarcoma × Clear all
NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
177 enrolled 25 charts
BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡